In the ADR treatment shFUT4 LSCs model, the primary tumor volume was found to decrease with ADR treatment, but overall the decrease was at a significantly faster rate than the untreated group (Fig. 2k), demonstrating that down-regulation of FUT4 could overcome drug resistance in LSCs of AML. This evidence concerns the gene FUT4 and acute myeloid leukemia.